Victory Capital Management Inc Xencor Inc Transaction History

Victory Capital Management Inc

  • $99 Billion
  • Q3 2024

A detailed history of Victory Capital Management Inc transactions in Xencor Inc stock. As of the latest transaction made, Victory Capital Management Inc holds 11,655 shares of XNCR stock, worth $273,892. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,655
Previous 13,204 11.73%
Holding current value
$273,892
Previous $249,000 6.02%
% of portfolio
0.0%
Previous 0.0%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024
SELL
$15.7 - $21.65 $24,319 - $33,535
-1,549 Reduced 11.73%
11,655 $234,000
Q2 2024

Aug 05, 2024
SELL
$18.21 - $24.5 $8,048 - $10,829
-442 Reduced 3.24%
13,204 $249,000
Q1 2024

May 03, 2024
SELL
$18.65 - $26.52 $204,982 - $291,481
-10,991 Reduced 44.61%
13,646 $301,000
Q4 2023

Feb 05, 2024
BUY
$16.53 - $21.42 $57,474 - $74,477
3,477 Added 16.43%
24,637 $523,000
Q3 2023

Nov 06, 2023
BUY
$20.08 - $25.39 $33,332 - $42,147
1,660 Added 8.51%
21,160 $426,000
Q2 2023

Jul 27, 2023
SELL
$24.77 - $29.9 $50,109 - $60,487
-2,023 Reduced 9.4%
19,500 $486,000
Q1 2023

May 02, 2023
SELL
$25.95 - $36.95 $278,832 - $397,027
-10,745 Reduced 33.3%
21,523 $600,000
Q4 2022

Feb 10, 2023
BUY
$24.79 - $30.86 $106,671 - $132,790
4,303 Added 15.39%
32,268 $840,000
Q4 2022

Feb 09, 2023
SELL
$24.79 - $30.86 $551,676 - $686,758
-22,254 Reduced 44.31%
27,965 $728,000
Q3 2022

Nov 02, 2022
BUY
$24.62 - $32.44 $534,574 - $704,369
21,713 Added 76.17%
50,219 $1.31 Million
Q2 2022

Aug 01, 2022
SELL
$19.74 - $29.01 $62,950 - $92,512
-3,189 Reduced 10.06%
28,506 $780,000
Q1 2022

May 04, 2022
BUY
$26.68 - $41.63 $222,351 - $346,944
8,334 Added 35.67%
31,695 $792,000
Q4 2021

Feb 07, 2022
BUY
$33.67 - $43.44 $28,855 - $37,228
857 Added 3.81%
23,361 $937,000
Q3 2021

Nov 02, 2021
BUY
$30.65 - $35.68 $144,913 - $168,695
4,728 Added 26.6%
22,504 $735,000
Q2 2021

Aug 03, 2021
SELL
$34.33 - $44.68 $26,708 - $34,761
-778 Reduced 4.19%
17,776 $613,000
Q1 2021

May 04, 2021
SELL
$40.81 - $53.88 $33,545 - $44,289
-822 Reduced 4.24%
18,554 $799,000
Q4 2020

Feb 01, 2021
SELL
$36.63 - $47.63 $27,875 - $36,246
-761 Reduced 3.78%
19,376 $845,000
Q3 2020

Nov 09, 2020
SELL
$30.09 - $43.02 $191,342 - $273,564
-6,359 Reduced 24.0%
20,137 $781,000
Q2 2020

Aug 07, 2020
BUY
$27.76 - $33.42 $10,076 - $12,131
363 Added 1.39%
26,496 $858,000
Q1 2020

May 04, 2020
SELL
$20.69 - $37.79 $59,400 - $108,495
-2,871 Reduced 9.9%
26,133 $781,000
Q4 2019

Feb 06, 2020
BUY
$32.75 - $41.43 $94,713 - $119,815
2,892 Added 11.08%
29,004 $997,000
Q4 2019

Feb 04, 2020
SELL
$32.75 - $41.43 $58,229 - $73,662
-1,778 Reduced 6.38%
26,112 $886,000
Q3 2019

Nov 12, 2019
SELL
$33.73 - $46.27 $740,440 - $1.02 Million
-21,952 Reduced 44.04%
27,890 $941,000
Q2 2019

Aug 15, 2019
SELL
$29.6 - $40.93 $1.01 Million - $1.39 Million
-34,000 Reduced 40.55%
49,842 $2.04 Million
Q1 2019

May 03, 2019
SELL
$27.85 - $38.09 $25,900 - $35,423
-930 Reduced 1.1%
83,842 $2.6 Million
Q4 2018

Feb 05, 2019
BUY
$32.39 - $42.05 $1.64 Million - $2.13 Million
50,683 Added 148.68%
84,772 $3.07 Million
Q3 2018

Nov 01, 2018
SELL
$35.69 - $47.65 $59,281 - $79,146
-1,661 Reduced 4.65%
34,089 $1.33 Million
Q2 2018

Aug 02, 2018
SELL
$28.41 - $42.41 $67,161 - $100,257
-2,364 Reduced 6.2%
35,750 $1.32 Million
Q1 2018

May 04, 2018
BUY
$21.18 - $33.78 $88,108 - $140,524
4,160 Added 12.25%
38,114 $1.14 Million
Q4 2017

Feb 01, 2018
BUY
$19.29 - $24.83 $85,068 - $109,500
4,410 Added 14.93%
33,954 $744,000
Q3 2017

Oct 27, 2017
SELL
$19.61 - $23.35 $16,276 - $19,380
-830 Reduced 2.73%
29,544 $678,000
Q2 2017

Aug 07, 2017
BUY
N/A
30,374
30,374 $641,000

Others Institutions Holding XNCR

# of Institutions
216
Shares Held
71.7M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.4B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email